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We found serologic evidence for the circulation of Mid-
dle East respiratory syndrome coronavirus among drome-
dary camels in Nigeria, Tunisia, and Ethiopia. Circulation of 
the virus among dromedaries across broad areas of Africa 
may indicate that this disease is currently underdiagnosed 
in humans outside the Arabian Peninsula.
A novel betacoronavirus, Middle East respiratory syn-drome coronavirus (MERS-CoV), was identified as 
the cause of severe respiratory disease in humans during 
2012 (1). In August 2013, dromedary camels (Camelus 
dromedarius) were implicated for the first time as a pos-
sible source for human infection on the basis of the pres-
ence of MERS-CoV neutralizing antibodies in dromedaries 
from Oman and the Canary Islands of Spain (2). Since then, 
the presence of MERS-CoV antibodies in dromedaries has 
been reported in Jordan (3), Egypt (4,5), the United Arab 
Emirates (6,7), and Saudi Arabia (8,9). In October 2013, 
analysis of an outbreak associated with 1 barn in Qatar (10) 
found dromedaries and humans to be infected with nearly 
identical strains of MERS-CoV. Further proof of wide-
spread circulation of MERS-CoV among dromedaries was 
provided by studies from Egypt and Saudi Arabia (5,9). 
These findings have raised questions about the geographic 
distribution of MERS-CoV among camel populations else-
where. Here, we report our assessment of the geographic 
distribution of MERS-CoV circulation among dromedaries 
in Africa by serologic investigation of convenience sam-
ples from these animals in Nigeria, Tunisia, and Ethiopia.
The Study
In Nigeria, serum samples from 358 dromedaries that 
were raised for meat production were collected at abattoirs 
in 4 provinces (Kano, n = 245; Sokoto, n = 51; Borno, n 
= 51; and Adamawa, n = 11; Figure 1, panel A) during 
2010–2011 for testing for peste des petits ruminants virus. 
The ages of the animals ranged from 4 to 15 years. The abat-
toirs also served the neighboring countries of Chad, Niger, 
and the Central African Republic. In Tunisia, serum sam-
ples from 204 dromedaries that were 1 to 16 years of age 
were collected in 3 provinces in 2009 and 2013 (Figure 1, 
panel B). Samples were collected from 155 dromedaries in 
Sidi Bouzid Province from 27 herds that were kept for meat 
production and from 39 dromedaries in Kebili Province 
from 16 herds that were kept for tourist rides; samples from 
both provinces had originally been collected for a study in-
vestigating the presence of Anaplasma phagocytophilum. 
Samples were collected from 10 dromedaries from Sousse 
Province that were kept for meat production because they 
were suspected of being infected with Trypanosoma evansi. 
In Ethiopia, samples from 188 dromedaries, 1 to 13 years 
of age, were collected as part of a study evaluating the pres-
ence of toxoplasmosis and respiratory tract diseases in 3 
provinces (Afar, n = 118; Somalia, n = 11; and Oromia, n = 
59; Figure 1, panel C) during 2011–2013. All samples were 
taken by jugular vein puncture according to local laws, and 
serum samples were stored at –20°C until testing. All serum 
samples were shipped to the Erasmus MC laboratory in the 
Netherlands in agreement with Dutch import regulations.
The serum samples were tested for the presence of IgG 
antibodies reactive with S1 antigens against MERS-CoV 
(residues 1–747), severe acute respiratory syndrome CoV 
(residues 1–676), and human CoV OC43 (residues 1–760) 
by using extensively validated protein-microarray tech-
nology, as described (2,3,6,11). Results were expressed 
as relative mean fluorescent intensity (RFU) for each set 
of quadruplicate spots of antigen, with a cutoff of 4,000 
RFU as used by Meyer et al. (6). Human CoV OC43 S1 
was used as a proxy for bovine coronavirus (BCoV), the 
latter of which is known to circulate commonly in drom-
edaries (7,12). High percentages of animals seropositive 
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for MERS-CoV were observed in Nigeria and Ethiopia; 
the overall seropositivity was 94% in adult dromedaries in 
Nigeria and 93% and 97% for juvenile and adult animals, 
respectively, in Ethiopia (Table 1). All provinces in which 
dromedaries were sampled in both countries showed high 
rates of seropositivity (Figure 1). The overall seropositivity 
in dromedaries in Tunisia was 30% for animals ≤2 years of 
age and 54% for adult animals. Seropositivity of 36% and 
40% was observed in Sidi Bouzid and Sousse Provinces, 
respectively, and 100% of the dromedaries in the southern 
province of Kebili were seropositive. Array results were 
confirmed on a selection of positive and negative serum 
samples (n = 14 per country) in MERS-CoV neutralization 
tests performed as described (2) (Table 2). Serum samples 
from 72%, 82%, and 67% of the dromedaries from Nigeria, 
Ethiopia, and Tunisia, respectively, reacted with the OC43 
antigen, confirming common circulation of BCoV in cam-
elids (7,12). All samples tested negative for severe acute 
respiratory syndrome CoV (data not shown).
Conclusions
Since the discovery of MERS-CoV in 2012, accu-
mulating serologic and molecular evidence demonstrates 
that the virus in dromedaries is genetically very similar 
to MERS-CoV in humans and points to the conclusion 
that dromedary camels are reservoirs for human infec-
tion. MERS-CoV genomic fragments have been detected 
in dromedaries in Qatar (10) and Saudi Arabia (9); near 
full-genome sequences have been generated from drom-
edaries in Egypt (5) and full-genome sequences have been 
generated from dromedaries in Saudi Arabia (13). Here, we 
show serologic evidence for circulation of MERS-CoV or 
MERS-like CoV in dromedaries in countries in East, West, 
and North Africa, with possible herd-specific differences in 
prevalence in Tunisia. The lower seropositivity observed in 
herds raised for meat production in Tunisia might reflect a 
high turnover of camels with a continuous introduction of 
animals unexposed to the MERS-CoV into these herds. No 
camels imported from neighboring countries were found 
at the meat-producing farms in Sidi Bouzid and Sousse, 
only camels purchased from other farms in the same area 
or other areas in Tunisia. However, animals are frequently 
moved between Libya and Kebili for trade.
Samples in this study were collected during 2009–
2011, confirming observations by us and others (6) that 
the virus circulated well before March 2012, which is the 
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Figure 1. Countries and provinces 
sampled in this study: A) Nigeria, 
B)Tunisia, and C) Ethiopia. Black 
outline indicates provinces in 
which samples were collected. 
Serologic results are indicated 
in each province as percentage 
seropositive for Middle East 
respiratory syndrome coronavirus 
(total no. dromedaries tested). 
Maps adapted from http://d-maps.
com/index.php
estimated time of identification of the most common ances-
tor for the MERS-CoV strains found in humans to date (14). 
The earliest serologic indication for circulation of MERS-
CoV or MERS-like CoV in dromedaries was observed in 
1992; however, this result was based on results of a whole-
virus ELISA with undescribed specificity (9). On the basis 
of well-validated array and neutralization tests, the study of 
dromedaries in the United Arab Emirates showed the pres-
ence of MERS-CoV or MERS-Cov–like antibodies as early 
as 2003 (6). The accumulated data on MERS-CoV serol-
ogy in dromedaries (Figure 2; Table 1) show circulation of 
MERS-CoV or MERS-like CoV in dromedaries in Africa 
and the Arabian Peninsula well before 2012, when the first 
cases in humans were identified, and show overall high lev-
els of seropositivity, including in animals from countries 
without reported human cases. 
A question raised by these findings is whether human 
cases occur outside the Arabian Peninsula and if such cases 
are currently underdiagnosed in Africa. In addition, for the 
whole region, the possibility exists that MERS-CoV ill-
ness occurred before its discovery in 2012 and that such 
infection has been overlooked in the areas with evidence for 
virus circulation among animals during the past 10 years. 
Retrospective studies of cohorts of humans with respiratory 
illnesses of unknown etiology should address this notion. 
Alternative explanations for the lack of cases in Africa 
could be the following: a different risk profile, for instance, 
related to demographics and local practices; or subtle genetic 
differences in the circulating virus strain. Full-genome se-
quencing, virus isolation, and phenotypic characterization of 
viruses circulating outside the Arabian Peninsula will resolve 
this issue. Meanwhile, awareness of MERS-CoV infections 
should be raised among clinicians in Africa.
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Table 1. Overview of serologic evidence for Middle East respiratory syndrome coronavirus among dromedary camels, Africa and the 
Arabian Peninsula 
Country Year No. camels* 
% Middle East respiratory syndrome 
coronavirus antibodies Reference 
United Arab Emirates 2013 500 (A,J) 96†,‡,§,¶ (6) 
 2013 59 (A) 97#, 100**, 98§ (7) 
 2003 151 (A) 100‡,§ (6) 
Egypt 2013 110 (A) 94§, 98†† (4) 
 2013 17 (A) 82†† (5) 
Spain (Canary Islands) 2012–2013 97 (A) 14§,¶ (2) 
 2012–2013 8 (J) 13§,¶ (2) 
Ethiopia 2010–2011 31 (J) 93¶ This study 
 2010–2011 157 (A) 97¶ This study 
Ethiopia, Sudan 2013 35 (A) 97†† (5) 
Jordan 2013 11 (J) 100§,¶ (3) 
Nigeria 2010–2011 358 (A) 94¶ This study 
Oman 2013 50 (A) 100§,¶ (2) 
Qatar 2013 14 (A) 100§,¶ (10) 
Saudi Arabia 2010–2013 65 (J) 72†† (8) 
 2010–2013 245 (A) 95†† (8) 
 2013 104 (J) 55‡‡ (9) 
 2013 98 (A) 95‡‡ (9) 
 2010 21 (J) 76‡‡ (9) 
 2010 23 (A) 91‡‡ (9) 
 2009 56 (J) 72‡‡ (9) 
 2009 26 (A) 92‡‡ (9) 
 2004 6 (A) 100‡‡ (9) 
 1996 6 (A) 100‡‡ (9) 
 1994 123 (A) 93‡‡ (9) 
 1993 2 (A) 100‡‡ (9) 
 1992 1 (A) 100‡‡ (9) 
Tunisia 2009 46 (J) 30¶ This study 
 2009 158 (A) 54¶ This study 
*Camel age range indicated where known. J, juvenile ≤2 y of age; A, adult >2 y of age. 
†Determined by recombinant spike immunofluorescence assay.  
‡Determined by neutralization test. 
§Determined by nucleocapsid western blot. 
¶Determined by S1 micro-array.  
#Determined by whole virus IFA. 
**Determined by pseudoparticle neutralization test. 
††Determined by complete virus infected cell ELISA. 
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Figure 2. Geographic distribution of 
serologic evidence for Middle East 
respiratory syndrome coronavirus 
(MERS-CoV) or MERS-like CoV 
circulation in dromedaries in 
Africa and the Arabian Peninsula. 
Gray shading indicates countries 
with seropositive dromedaries; 
solid black outline indicates 
countries with primary human 
cases; dotted outline indicates 
countries with secondary human 
cases. For each country with 
affected dromedaries, the year 
of sampling, % seropositive, total 
number tested, and age group 
are indicated. A, adult, >2 years of 
age; J, juvenile, ≤2 years of age. 
Details on serologic tests used and 
references are in Table 1.
